DRMA logo

DERMATA THERAPEUTICS INC

DRMANASDAQ
🏆 #5438 by market capUS Equity
$352.01▲ $20.49 (+5.82%)
Simulated price
🔔
Track DRMA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.8%
7d▲ 30245.7%
14d▲ 30245.7%
30d▲ 23604.4%
ytd▲ 14784.1%
1y▲ 6579.5%
🏦Market Cap
$776,975
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$350.53 – $358.75
52-Week Range
$0.95 – $5.87
Volume
$4.98B
Avg Volume
$3.89B
Shares Outstanding
681,557
Next Earnings
Dec 4, 2026

Fundamentals Snapshot

Annual Revenue
$66,408
Last Q Revenue
$18,201
P/E Ratio
-0.3
P/S Ratio
0.0x
EPS (TTM)
$-2.08
Dividend Yield
0.00%
Dilution (1yr)
+686.9%

Why Investors Own DRMA

  • ✓High-growth profile — revenue up +58.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 31% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DRMA logo

DERMATA THERAPEUTICS INC

DRMA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −37.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$8M▼ −30.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.2M▲ +686.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$4M YoY
StockOtter · stockotter.space

About DERMATA THERAPEUTICS INC

Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$422.98
▲ +20.2% Upside
High Target$463.54
Low Target$359.57
Based on 24 analysts

Latest News & Updates

🚀
Reuters·2h ago

DERMATA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift DRMA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

DERMATA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.